KEYNOTE-604: Pembrolizumab Missed OS Endpoint in First-Line SCLC, but Appeared to Prolong Survival in Some Patients
The drug did, however, significantly improve progression-free survival.
The drug did, however, significantly improve progression-free survival.
Encouraging activity noted in several tumor types.
The researchers found that patients who received pelvic radiation had a decreased chance of live birth.
Analysis of biomarkers to predict response to pembrolizumab are ongoing.
Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.
A longer treatment-free survival interval associated with surgery may contribute to overall survival.
The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.
A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.
SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.
The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.